Core Insights - The innovative drug sector is experiencing a significant bull market, with the entry threshold for top-performing stocks raised considerably [1] - In 2024, the median stock price increase for the top 10 innovative drug companies was 57.9%, while in 2025, this surged to a median increase of 495.41%, with the highest increase reaching 1824% [2] Group 1: Top Performing Companies - The top-performing stock in 2025 was Beihai Kangcheng, with an astonishing annual increase of 1824%, surprising many in the market [4] - Following Beihai Kangcheng, the second highest was Sanleaf Biotech, which saw an increase of 870%, despite facing significant operational challenges [10] - Yaojie Ankang ranked third with a 773% increase, although its valuation raised concerns due to its limited clinical progress [12] - Heber Pharmaceuticals achieved a 553% increase, driven by its dual-engine model of R&D and business development [16] - Xuan Bamboo Biotech, a newly listed company, experienced a 507% increase, attributed to its new stock status and positive clinical data [20] Group 2: Market Dynamics and Trends - The market has seen a trend of speculative trading, with some companies experiencing price surges not necessarily backed by fundamental improvements [4] - The rise of companies like Heber Pharmaceuticals and Rongchang Biotech illustrates that long-term undervalued firms can achieve significant valuation recovery through continuous R&D and commercialization breakthroughs [4][30] - The innovative drug sector's growth is heavily influenced by liquidity and market sentiment, with many price increases based on speculative expectations rather than solid fundamentals [39] Group 3: Company-Specific Developments - Beihai Kangcheng's stock price recovery was linked to strategic capital injections, resolving its cash flow crisis [7] - Sanleaf Biotech's stock price rebound was primarily driven by its RSV vaccine pipeline, despite facing significant financial pressures [10][11] - Yaojie Ankang's rapid valuation increase raised questions about its sustainability, given its limited clinical advancements [13][14] - Heber Pharmaceuticals' growth was supported by strategic partnerships and a robust technology platform, enhancing investor confidence [18][19] - Rongchang Biotech's stock performance was bolstered by successful product approvals and strategic financing, improving its market outlook [31]

Core Insights - The innovative drug sector is experiencing a significant bull market, with the entry threshold for top-performing stocks raised considerably [1] - In 2024, the median increase for the top 10 innovative drug companies was 57.9%, with the highest increase reaching 132.6%. In 2025, this trend intensified, with the median increase for the top 10 soaring to 495.41% and the highest increase hitting 1824% [2] Group 1: Top Performing Companies - Beihai Kangcheng-B achieved the highest increase in 2025, with a staggering 1824% rise, surprising many in the market [5] - Sanleaf Biotech-B followed with an impressive 870% increase, despite facing significant operational challenges, including a cash flow crisis and a major refund demand from GAVI [10][11] - Yaojie Ankang-B, despite being controversial, saw its stock price rise nearly ninefold in a short period, reaching a market cap close to 270 billion HKD [12][13] - Heptagon Pharmaceuticals-B ranked fourth with a 553% increase, driven by its dual-engine model of R&D and business development [14][15] - Xuan Bamboo Biotech-B, a newly listed company, achieved a 507% increase, benefiting from positive clinical trial results and inclusion in national insurance directories [17][18] - Deqi Pharmaceuticals-B saw a 483% increase, attributed to its innovative AI-driven T-cell connector platform [19][20] - Jike Si-B experienced a 401% increase, driven by its advancements in KRAS-targeted therapies [22][23] - Rongchang Biotech achieved a 400% increase, with its product Taite Xip demonstrating significant potential across multiple indications [24][25] - Paige Biotech saw a 342% increase, largely due to its GLP-1 pipeline's market momentum [27] - Baiaosaitu-B rounded out the top ten with a 315% increase, supported by strong revenue growth and positive market expectations for its upcoming H+A listing [28][30] Group 2: Market Dynamics - The surge in stock prices for many companies is not solely based on fundamental improvements but also reflects speculative trading behaviors [4] - The innovative drug sector's long-term health relies on the emergence of stocks driven by genuine innovation rather than short-term speculation [4] - The market's focus on liquidity and sentiment has led to significant price increases, but these may not be sustainable as market conditions change [31]

Core Viewpoint - Dr. Li Jiaqiu has resigned as the Executive Director and General Manager of Xuan Zhu Bio-B (02575) to dedicate more time to other business commitments [1] Group 1 - The resignation will take effect only after a new Executive Director is appointed at the company's shareholders' meeting [1] - Dr. Li has committed to continue fulfilling his duties as Executive Director diligently and faithfully during the transition period [1]

为确保企业管治及董事会运作顺利过渡，李博士承诺会继续忠实及勤勉尽责地履行执行董事职责。辞任 仅于本公司股东大会委任新执行董事加入董事会后生效。 智通财经APP讯，轩竹生物-B(02575)发布公告，李嘉逵博士辞任本公司执行董事及总经理，以投放更多 时间于其他业务承担。 ...

格隆汇1月2日丨轩竹生物-B(02575.HK)宣布，李嘉逵辞任公司执行董事及总经理，以投放更多时间于其 他业务承担。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 Xuanzhu Biopharmaceutical Co., Ltd. 軒竹生物科技股份有限公司 （一家於中華人民共和國註冊成立的股份有限公司） （股份代號：2575） 執行董事兼總經理辭任 董 事 會 謹 此 向 李 博 士 為 本 公 司 作 出 之 寶 貴 貢 獻 致 以 衷 心 感 謝。 承董事會命 軒 竹 生 物 科 技 股 份 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」）董 事（「董 事」）會（「董事會」）謹 此 宣 佈 李 嘉 逵 博 士（「李博士」）辭 任 本 公 司 執 行 董 事 及 總 經 理，以 投 放 更 多 時 間 於 其 他 業 務 承 擔（「辭 任」）。 李博士確認(i)彼 與 董 事 會 並 無 任 何 意 見 分 歧；及(ii)並無有關辭任之其他事宜 須 提 請 聯 交 所 及 本 ...

Core Viewpoint - The "Technology Empowerment · Capital Breakthrough" sharing conference revealed the list of outstanding companies, highlighting the recognition of exceptional performance in the IPO sector [1] Group 1: Company Recognition - XuanZhu Biotechnology - B (2575.HK) won the "Annual Outstanding Investment Value IPO" award at the "Golden Grid Award" annual selection, acknowledging its strong performance in core business and significant growth potential in its industry [1]

Core Viewpoint - The "Annual Outstanding Investment Value IPO" awards recognize new listed companies that excel in core business, performance growth, and shareholder value creation, highlighting their significant growth potential and competitive advantages in their respective industries [4]. Group 1: Award Recipients - Eight companies received the "Annual Outstanding Investment Value IPO" award, including Different Group (06090.HK), Cao Cao Travel (02643.HK), Dipo Technology (01384.HK), Geek+ (02590.HK), Leshu (02698.HK), Tudatong (02665.HK), Xuan Bamboo Biotechnology-B (02575.HK), and Yingshi Innovation (688775.SH) [1]. - The ranking of the award recipients is not in any particular order and is based on the first letter of the company names [1]. Group 2: Evaluation Criteria - The evaluation for the awards was conducted through quantitative data analysis and an expert review panel [4]. - The awards aim to create a reference value for listed companies and unicorn companies within the investment community, emphasizing a global perspective with a focus on China [4]. Group 3: Coverage of the Awards - The "Golden Award" listing company evaluation covers all listed companies and unicorns on the Hong Kong Stock Exchange, Shanghai Stock Exchange, Shenzhen Stock Exchange, New York Stock Exchange, American Stock Exchange, and NASDAQ [4].

Core Viewpoint - XuanZhu Biotech's stock price has surged significantly, reflecting strong investor confidence in its innovative capabilities, with a cumulative increase of 700% since its IPO as of December 11 [1] Group 1: Company Performance - XuanZhu Biotech has launched three innovative drugs in three years, demonstrating its efficient R&D conversion system [5] - The company has successfully commercialized three innovative drugs in the "digestion + oncology" fields within a short span, showcasing its ability to address clinical pain points [5][6] - The stock price increase is attributed to the clinical value realization of its core products and the company's effective R&D strategy [5][7] Group 2: Product Details - Annelazole Sodium addresses two major clinical pain points in the PPI market: genetic adaptability and renal safety, achieving a significant reduction in efficacy differences among patients with different genetic types [6] - The drug has been included in the national medical insurance directory in its first year, filling a clinical demand gap [6] - The two oncology drugs, Pyrocil and Diroac, target unmet needs in HR+/HER2- breast cancer and ALK-positive NSCLC, respectively, enhancing the company's oncology pipeline [7][12] Group 3: Market Potential - The market for CDK4/6 inhibitors for breast cancer is projected to reach 9.8 billion yuan by 2030, with Pyrocil expected to penetrate the market rapidly due to its competitive clinical data [11] - The potential market for ALK inhibitors in NSCLC is estimated to reach 7.8 billion yuan by 2030, indicating a significant growth opportunity for Diroac [13] - The innovative drugs' clinical data support a shift in the industry valuation focus from pipeline thickness to individual product value density, positioning XuanZhu Biotech as a potential leader in niche markets [15]

Group 1: 52-Week Highs - A total of 44 stocks reached their 52-week highs as of December 12, with notable performers including Yuanmei Optoelectronics (08311) at 105.56%, Jinglian Group (01751) at 25.54%, and Xuan Bamboo Biotechnology - B (02575) at 23.60% [1] - The closing prices and peak prices for the top three stocks are as follows: Yuanmei Optoelectronics closed at 0.154 with a peak of 0.185, Jinglian Group closed at 1.850 with a peak of 2.310, and Xuan Bamboo Biotechnology - B closed at 82.950 with a peak of 96.900 [1] Group 2: 52-Week Lows - The report also highlighted stocks that reached their 52-week lows, with notable declines including Times China Holdings (01233) at -13.79%, Cornerstone Holdings (01592) at -11.36%, and HMVOD Video (08103) at -9.09% [2] - The closing prices and lowest prices for the top three declining stocks are as follows: Times China Holdings closed at 0.106 with a low of 0.100, Cornerstone Holdings closed at 0.198 with a low of 0.195, and HMVOD Video closed at 0.129 with a low of 0.120 [2]